New Zealanders will soon be able to receive 12-month prescriptions for their medicines, delivering savings to patients on long-term medications.
In a significant shift aimed at enhancing healthcare efficiency and reducing patient costs, the New Zealand Government announced in today's Budget 2025 that, starting from the first quarter of 2026, prescribers will be permitted to issue 12-month prescriptions for medications, provided it is clinically appropriate and safe to do so. This change is expected to benefit patients on stable, long-term medications such as those for asthma, diabetes, and high blood pressure.
Currently, patients are required to visit their general practitioners every three months to renew prescriptions, incurring additional costs and time. Health Minister Simeon Brown highlighted that this new policy could save patients up to NZD 105 annually in GP fees. Moreover, it aims to alleviate the administrative burden on healthcare professionals, allowing them to focus more on patients with complex health needs.
The Budget allocates NZD 91 million over four years to support this initiative, covering the anticipated increase in dispensed medications. While patients will still collect their medications from pharmacies every three months, the need for frequent doctor visits for prescription renewals will be eliminated.
Associate Health Minister David Seymour emphasised that this change reflects a commitment to a more adaptable and patient-centred healthcare approach.
He said, "Requiring patients on stable, long-term medications to visit GPs four times a year to renew a prescription only costs them money and reduces accessibility. A 12-month prescription in these cases is just common sense."
This policy is part of a broader NZD 7 billion increase in health funding over four years, as outlined in Budget 2025. The overall health budget now tops NZD 3.1 billion for the next year, marking a 4.77 percent increase.
While the move has been welcomed for its potential to streamline healthcare services and reduce patient costs, experts caution that it is crucial to ensure that patients on medications requiring close monitoring continue to receive appropriate oversight. The success of this initiative will depend on its careful implementation and the ongoing assessment of patient outcomes.
More news here.
